Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

This study has been completed.
MedImmune LLC
Information provided by:
GlaxoSmithKline Identifier:
First received: June 5, 2008
Last updated: NA
Last verified: June 2008
History: No changes posted

The goals of this study are to describe the safety, reactogenicity and immunogenicity of MEDI-517 with and without adjuvant in HPV-naïve humans. Long-term immune data is collected.

This study was originally performed by MedImmune. However, GSK is now responsible for the clinical development of the HPV vaccine.

Condition Intervention Phase
Prophylaxis HPV-16/18 Infections and Cervical Neoplasia
Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine
Biological: MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3
Biological: MEDI-517 HPV-16/18 VLP vaccine without adjuvant
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Study to Evaluate the Safety and Immunogenicity of MEDI-517, a Virus-Like Particle Vaccine Against Human Papillomavirus Types 16 and 18, When Formulated With Aluminum Hydroxide, AS04, or Without Adjuvant, in Healthy Adult Female Volunteers

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Solicited adverse event rates (including injection site and systemic reactions) [ Time Frame: For 7 days after each injection ]
  • Solicited adverse event rates [ Time Frame: For 30 days after each injection ]
  • Serious adverse event rates [ Time Frame: From first injection through 6 months after last injection ]
  • Laboratory assessments (Chemistry and Hematology parameters) [ Time Frame: Study Days 0, 30 and 210 ]
  • Vital signs (temperature, blood pressure, pulse rate, respiratory rate) [ Time Frame: At the time of each injection and 30 minutes after each injection ]
  • Serum ELISA titers against HPV-16 and HPV-18 [ Time Frame: 30 days after the third injection ]

Secondary Outcome Measures:
  • Serum ELISA titers against HPV-16 and HPV-18 [ Time Frame: Study Days 0, 7, 30, 60, 180, 210, and 360, and at 18, 24, 36, and 48 months ]
  • Neutralization titers against HPV-16 and HPV-18 [ Time Frame: Study Days 0, 60, 210 and 360 ]
  • Inhibitory ELISAs [ Time Frame: Study Days 0, 60, 210, and 360, and at 18, 24, 36, and 48 months ]
  • Lymphoproliferative, IL-5, and IFN-γ assays [ Time Frame: Study Days 0, 60, 210, and 360, and at 18, and 24 months ]

Enrollment: 60
Study Start Date: October 2000
Study Completion Date: January 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A
Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
Biological: MEDI-517 HPV-16/18 VLP AS04 vaccine
IM injection
Experimental: Group B
Formulation 2 of the vaccine [with Al(OH)3]
Biological: MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3
IM injection
Experimental: Group C
Formulation 3 of the vaccine (without adjuvant)
Biological: MEDI-517 HPV-16/18 VLP vaccine without adjuvant
IM injection

Detailed Description:
This is a Phase II, double-blind, randomized, comparative trial of three formulations of MEDI-517 given at 0, 30, and 180 days by intramuscular injection. The volunteers in this study will be healthy females 18 through 30 years of age. The study collects safety, reactogenicity and immunogenicity data of MEDI-517 with and without adjuvant. Extended follow-up will provide long-term immune response data.

Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Females 18 through 30 years of age (must not have reached the 31st birthday)
  • Written informed consent obtained from the volunteer
  • Unless previously surgically sterilized, agrees to use an effective method of birth control beginning 30 days before the first study injection and continuing through 60 days after the final study injection
  • Must have a negative serum pregnancy test within 21 days of study entry and must not be breast feeding
  • Healthy by medical history and physical examination
  • Seronegative for HPV-16 and HPV-18 antibody by ELISA within 21 days of study entry
  • Cervical specimen negative for high-risk HPV DNA using the Digene Hybrid Capture® II HPV test (high-risk types Probe B) within 21 days of study entry
  • Normal Pap smear, using the Cytyc ThinPrep® Pap Test, within 21 days of study entry
  • No evidence of anogenital HPV lesions or physical findings suggestive of other gynaecologic pathogens on pelvic examination within 21 days of study entry
  • Agrees to no other vaccines or experimental therapy until 30 days after the last study injection

Exclusion Criteria:

  • Acute illness or fever (oral temperature ≥ 99.5°F [37.5°C]) at start of the study
  • History or clinical manifestations of significant medical or psychiatric disorder
  • Use of immunosuppressive medication (inhaled and topical corticosteroids are permitted) within the previous 90 days or history of immunodeficiency
  • History of cancer
  • History of alcohol or drug abuse within the past 2 years
  • Abnormal laboratory blood values at screening. Other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant
  • Receipt of immunoglobulin or blood products within 90 days prior to study entry
  • History of abnormal Pap smear (other than a single prior report of ASCUS or indeterminate Pap smear with a subsequent normal report)
  • Genital herpes disease involving the cervix or with disease characterized on examination or by history by extensive external lesions. Volunteers with a history of recurrent genital herpes disease characterized by limited external lesions are eligible to participate in the study.
  • Positive tests for hepatitis C antibody, hepatitis B surface antigen, or HIV-1 antibody
  • Any prior receipt of any vaccine (experimental or otherwise) for treatment or prophylaxis of genital warts or other papillomavirus related condition. Any treatment of genital warts or other papillomavirus related condition within 6 months of randomization (local therapy for common skin and/or plantar warts is allowed)
  • Previous administration of any components of the investigational vaccine
  • Receipt of any experimental vaccine within 90 days prior to entry into this study
  • Receipt of any experimental drug therapy within 30 days or five half-lives of the experimental drug (if the half-life is known), whichever is longer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00693615

United States, Alabama
GSK Clinical Trials Call Center
Birmingham, Alabama, United States
United States, Louisiana
GSK Clinical Trials Call Center
New Orleans, Louisiana, United States
United States, New York
GSK Clinical Trials Call Center
Rochester, New York, United States
United States, Ohio
GSK Clinical Trials Call Center
Cincinnati, Ohio, United States
United States, Texas
GSK Clinical Trials Call Center
Austin, Texas, United States
United States, Utah
GSK Clinical Trials Call Center
Salt Lake City, Utah, United States
Sponsors and Collaborators
MedImmune LLC
Study Director: Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: Isabelle Harpigny, GSK Identifier: NCT00693615     History of Changes
Other Study ID Numbers: 580299/004  MI-CP055 
Study First Received: June 5, 2008
Last Updated: June 5, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
HPV, Vaccine

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on August 28, 2016